Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,073 total articles

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Senseonics Holdings, Inc. reported new real-world data at the American Diabetes Association Scientific Sessions showcasing the strong performance and patient adherence of its Eversense 365 implantable continuous glucose monitoring (CGM) system. The data from over 12,000 sensors confirm sustained accuracy and positive glycemic outcomes over a full y…

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

All In FutureTech Alliance (Nasdaq: AIFA) provided a strategic update on accelerating its transformation into an AI infrastructure platform leveraging optical technologies. Key developments include expanding the Hainan AIFA Silicon Photonics Supercomputing Center project into a broader Digital Industrial Park, progressing in governmental approvals …

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Cullinan Therapeutics reported initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in patients with refractory systemic lupus erythematosus (SLE) and difficult-to-treat rheumatoid arthritis (RA). Data demonstrated deep, dose-dependent B cell depletion in blood and tissue along with a f…

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

InterPrivate Investment Partners V, Inc., a blank check company focused on mergers and acquisitions, has closed its initial public offering of 20,125,000 units at $10 per unit, raising $201.25 million before expenses. The units began trading on Nasdaq under the ticker symbol IPVVU, with plans to list their Class A shares and warrants separately in …

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics has closed an $8.5 million private placement priced at-the-market on Nasdaq, with potential to raise an additional $15.2 million through warrant exercises. The proceeds are expected to extend the company's cash runway into Q1 2027, supporting FDA submission and subsequent commercialization of its near-patient sepsis testing prod…

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind Corporation announced new clinical and real-world data on Afrezza, its inhaled insulin product, at the ADA 2026 Scientific Sessions. The data build on the recent FDA approval for pediatric use and highlight Afrezza’s safety, efficacy, and patient treatment satisfaction in children, adolescents, and gestational diabetes patients. Additional…

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion presented promising clinical and translational data for its oral menin inhibitor icovamenib at the ADA 86th Scientific Sessions, demonstrating benefits in type 1 and type 2 diabetes including improved insulin secretion, glycemic control, muscle preservation, and fat reduction. Additionally, the company announced expansion of its Phase…

Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease in May 2026 of 4.1% Compared to 2025

Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease in May 2026 of 4.1% Compared to 2025

Grupo Aeroportuario del Pacifico, which operates 12 airports in Mexico and two in Jamaica, reported a 4.1% decrease in total passenger traffic in May 2026 compared to May 2025. The decline was driven by decreases at key airports including Puerto Vallarta, Tijuana, Los Cabos, and Montego Bay, despite a passenger increase at Guadalajara airport. Avai…

Caliber Announces CFO Transition

Caliber Announces CFO Transition

Caliber (Nasdaq: CWD), a real estate and digital asset management platform, announced the departure of long-time CFO Jade Leung and appointed Michael Rosales as Acting CFO effective June 14, 2026. The company reaffirmed its 2026 financial guidance and emphasized that the CFO transition will not impact its strategy or outlook. A search for a permane…

dLocal to Report Second Quarter 2026 Financial Results

dLocal to Report Second Quarter 2026 Financial Results

dLocal Limited, a cross-border payment platform focused on emerging markets, announced it will release its second quarter 2026 financial results on August 13, 2026, followed by a conference call and webcast. The company facilitates global payment infrastructures connecting enterprises to local markets in Africa, Asia, the Middle East, and Latin Ame…

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics shares positive Phase 2b clinical data for aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity treatment, demonstrating significant and durable weight loss up to 16.2% over 36 weeks, alongside a favorable safety and tolerability profile. The data, published in Nature Medicine and presented at the American …

Liftoff Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Liftoff Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Liftoff Mobile, a leader in AI-powered performance marketing and monetization for mobile apps, completed its initial public offering (IPO) by selling 21.85 million shares at $23 per share. The underwriters fully exercised their option to purchase an additional 2.85 million shares, signaling strong market interest. Proceeds will be used to pay down …

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs, a clinical-stage biotech company focusing on monoclonal and bispecific DR3-blocking antibodies, will hold an investor call on June 8 to present comprehensive Phase 1 clinical data for its lead candidate SL-325. The data includes safety, pharmacokinetics, and immunogenicity results. SL-325 is a potential first-in-class treatment targe…

U.S. Global Investors Announces Restatement of EPS for Q3 2026; Reported Financial Strength Remains Unchanged

U.S. Global Investors Announces Restatement of EPS for Q3 2026; Reported Financial Strength Remains Unchanged

U.S. Global Investors announced a restatement of its earnings per share for the three- and nine-month periods ended March 31, 2026, due to an inadvertent omission affecting the weighted average shares calculation. The restatement led to a slight reduction in EPS ($0.02 for Q3 and $0.01 for nine months), but the company's net income, revenue, and as…

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jade Biosciences has successfully closed a public offering of 11.5 million shares at $15.00 each, including full exercise of the underwriters' option, raising gross proceeds of $172.5 million. The clinical-stage biotechnology company plans to use the net proceeds to advance clinical trials, preclinical studies, research, and manufacturing focused o…